| 2023-06-06 | -40.9% | legal | SEC EDGAR | NVCR 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-07-24 | -27.5% | earnings | Seeking Alpha | NovoCure GAAP EPS of -$0.36 beats by $0.03, revenue of $158.8M beats by $4.6M |
| 2025-07-24 | -27.5% | legal | SEC EDGAR | NVCR 8-K: 2.02 and (SEC Filing) |
| 2025-07-23 | -24.0% | earnings | Seeking Alpha | NovoCure Q2 2025 Earnings Preview |
| 2026-02-11 | +21.2% | news | Stock Titan | First new pancreatic cancer treatment in nearly 30 years is wearable - Stock Titan |
| 2023-07-27 | -17.7% | legal | SEC EDGAR | NVCR 8-K: 2.02 and (SEC Filing) |
| 2026-02-25 | +16.8% | earnings | Seeking Alpha | NovoCure Q4 2025 Earnings Preview |
| 2026-02-25 | +16.8% | news | Investing.com | Novocure stock jumps after Medicare billing restored - Investing.com |
| 2023-01-09 | -15.3% | legal | SEC EDGAR | NVCR 8-K: 2.02 and (SEC Filing) |
| 2021-07-29 | -15.3% | legal | SEC EDGAR | NVCR 8-K: 2.02 and (SEC Filing) |
| 2025-12-01 | -14.5% | executive | Seeking Alpha | Novocure names Frank Leonard as CEO |
| 2025-12-01 | -14.5% | legal | SEC EDGAR | NVCR 8-K: 5.02, 7.01 (SEC Filing) |
| 2024-05-02 | +13.8% | legal | SEC EDGAR | NVCR 8-K: 2.02 and (SEC Filing) |
| 2025-02-27 | -13.1% | legal | SEC EDGAR | NVCR 8-K: 2.02 and (SEC Filing) |
| 2026-02-05 | -12.9% | earnings | Seeking Alpha | NovoCure projects $13M monthly revenue hit as Medicare revokes billing privileges |
| 2026-02-05 | -12.9% | news | Investing.com India | Novocure stock hits 52-week low at $10.66 - Investing.com India |
| 2023-06-08 | -12.9% | legal | SEC EDGAR | NVCR 8-K: 5.02 and 5.07 (SEC Filing) |
| 2024-09-03 | -11.8% | legal | SEC EDGAR | NVCR 8-K: 5.02, 7.01, 8.01 (SEC Filing) |
| 2022-07-28 | -10.8% | legal | SEC EDGAR | NVCR 8-K: 2.02 and (SEC Filing) |
| 2024-01-18 | +10.4% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2026-03-27 | -9.9% | earnings | Zacks | Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates |
| 2024-01-08 | +9.4% | legal | SEC EDGAR | NVCR 8-K: 2.02 and (SEC Filing) |
| 2025-12-09 | +9.0% | executive | Sahm | Does NovoCure’s (NVCR) Internal CEO Transition Reinforce or Recast Its Tumor Treating Fields Strategy? - Sahm |
| 2021-12-07 | +9.0% | legal | SEC EDGAR | NVCR 8-K: 1.01, 8.01 (SEC Filing) |
| 2023-10-26 | -8.6% | legal | SEC EDGAR | NVCR 8-K: 2.02 and (SEC Filing) |
| 2021-10-28 | -8.6% | legal | SEC EDGAR | NVCR 8-K: 2.02 and (SEC Filing) |
| 2024-10-30 | -7.9% | legal | SEC EDGAR | NVCR 8-K: 2.02, 5.02 (SEC Filing) |
| 2026-02-26 | -7.8% | earnings | Seeking Alpha | NovoCure outlines $675M–$705M 2026 revenue target as new indications fuel growth |
| 2026-02-26 | -7.8% | earnings | Seeking Alpha | NovoCure Limited (NVCR) Q4 2025 Earnings Call Transcript |
| 2026-02-26 | -7.8% | earnings | Seeking Alpha | NovoCure GAAP EPS of -$0.22 beats by $0.19, revenue of $174.35M beats by $0.99M |
| 2026-02-26 | -7.8% | legal | SEC EDGAR | NVCR 8-K: 2.02 and (SEC Filing) |
| 2026-02-26 | -7.8% | earnings | ChartMill | Novocure Ltd (NASDAQ:NVCR) Reports Mixed Q4 2025 Results, Stock Falls on Revenue Miss - ChartMill |
| 2026-02-26 | -7.8% | earnings | Investing.com | Novocure Ltd earnings beat by $0.19, revenue topped estimates - Investing.com |
| 2025-07-25 | -7.6% | earnings | Seeking Alpha | NovoCure Limited 2025 Q2 - Results - Earnings Call Presentation |
| 2025-07-25 | -7.6% | earnings | Seeking Alpha | NovoCure Limited (NVCR) Q2 2025 Earnings Call Transcript |
| 2026-03-04 | +6.8% | legal | Stock Titan | [144] NovoCure Ltd SEC Filing - Stock Titan |
| 2022-05-26 | +6.6% | legal | SEC EDGAR | NVCR 8-K: 1.01 and 8.01 (SEC Filing) |
| 2022-02-24 | +6.4% | legal | SEC EDGAR | NVCR 8-K: 2.02 and (SEC Filing) |
| 2026-02-12 | +6.1% | legal | Seeking Alpha | NovoCure: FDA Approval For PC Unlocked With TTFields Expansion Opportunity Approaching |
| 2026-02-12 | +6.1% | legal | Seeking Alpha | Novocure shares surge after FDA approves Optune Pax for pancreatic cancer |
| 2026-02-12 | +6.1% | legal | Benzinga | NovoCure Stock Surges After FDA Approves Optune Pax - Benzinga |
| 2026-02-12 | +6.1% | news | Benzinga | Stock Market Today: Dow Jones, S&P 500 Futures Gain After Strong Jobs Report—Micron, Novocure, Fastly In - Benzinga |
| 2026-02-12 | +6.1% | news | MSN | NovoCure (NVCR) stock is trending overnight — here's what you should know - MSN |
| 2022-06-10 | -5.9% | legal | SEC EDGAR | NVCR 8-K: 5.02, 5.03, 5.07 (SEC Filing) |
| 2026-01-02 | +5.6% | news | Seeking Alpha | NovoCure: 2026 Pipeline Outlook Makes This Stock A Speculative Buy |
| 2023-02-23 | -5.6% | legal | SEC EDGAR | NVCR 8-K: 2.02 and (SEC Filing) |
| 2025-07-31 | +5.2% | expansion | Seeking Alpha | NovoCure: Cash Burn, A Costly Launch, And A Maturing Business Signal More Pain Ahead |
| 2025-11-06 | -5.0% | earnings | Seeking Alpha | NovoCure Limited 2025 Q3 - Results - Earnings Call Presentation |
| 2026-01-12 | -4.8% | earnings | Seeking Alpha | Novocure reports FY25 preliminary net revenues of $655.4M |
| 2026-01-12 | -4.8% | legal | SEC EDGAR | NVCR 8-K: 2.02 and (SEC Filing) |
| 2026-01-12 | -4.8% | news | Stock Titan | Cancer therapy Novocure hits record sales, awaits 2026 trial results - Stock Titan |
| 2025-01-13 | -4.7% | legal | SEC EDGAR | NVCR 8-K: 2.02 and (SEC Filing) |
| 2025-01-13 | -4.7% | earnings | Stock Titan | Novocure Reports Strong 19% Revenue Growth, Hits $605M as Cancer Treatment Platform Expands - Stock Titan |
| 2024-02-22 | -4.7% | legal | SEC EDGAR | NVCR 8-K: 2.02 and (SEC Filing) |
| 2025-10-30 | -4.2% | earnings | Seeking Alpha | Novocure outlines four-indication expansion and profitability target for 2027 as GBM growth continues |
| 2025-10-30 | -4.2% | earnings | Seeking Alpha | NovoCure Limited (NVCR) Q3 2025 Earnings Call Transcript |
| 2025-10-30 | -4.2% | earnings | Seeking Alpha | NovoCure GAAP EPS of -$0.33 beats by $0.09, revenue of $167M beats by $8.06M |
| 2025-10-30 | -4.2% | legal | SEC EDGAR | NVCR 8-K: 2.02 and (SEC Filing) |
| 2025-10-30 | -4.2% | earnings | ChartMill | Novocure (NASDAQ:NVCR) Q3 2025 Earnings: Revenue Beat and Narrower Loss Drive Shares Higher - ChartMill |
| 2026-04-01 | -4.1% | news | Business Wire | Novocure to Report First Quarter 2026 Financial Results |
| 2026-04-01 | -4.1% | earnings | Stock Titan | Novocure will post Q1 results before market open on April 30 - Stock Titan |
| 2026-04-20 | -3.8% | news | Stock Titan | [DEF 14A] NovoCure Ltd Definitive Proxy Statement - Stock Titan |
| 2021-12-30 | -3.6% | legal | SEC EDGAR | NVCR 8-K: 8.01 (SEC Filing) |
| 2026-04-10 | -3.5% | news | GuruFocus | NovoCure Ltd (NVCR) Stock Down 3.8% -- Now Undervalued? GF Score: 66/100 - GuruFocus |
| 2026-04-02 | -3.2% | news | Simply Wall St. | NovoCure (NVCR) Is Down 6.6% After Strong PANOVA-4 Phase 2 Data In Metastatic Pancreatic Cancer – Has The Bull Case Changed? |
| 2025-03-08 | +3.2% | news | Intellectia AI | NVCR Forecast — Price Prediction for 2026. Should I Buy NVCR? - Intellectia AI |
| 2025-10-29 | -3.1% | earnings | Seeking Alpha | NovoCure Q3 2025 Earnings Preview |
| 2026-02-06 | -3.0% | news | Seeking Alpha | Why NovoCure Is No Longer A Clear Sell At These Lows |
| 2026-03-09 | -2.9% | news | Zacks | Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment |
| 2024-12-17 | +2.7% | legal | SEC EDGAR | NVCR 8-K: 5.02 and (SEC Filing) |
| 2026-04-09 | -2.5% | legal | SEC EDGAR | NVCR 8-K: 5.02 and (SEC Filing) |
| 2026-04-09 | -2.5% | news | Stock Titan | NovoCure (NASDAQ: NVCR) boosts pay as Uri Weinberg assumes CMO duties - Stock Titan |
| 2022-01-10 | +2.4% | legal | SEC EDGAR | NVCR 8-K: 2.02 and (SEC Filing) |
| 2023-05-04 | +2.3% | legal | SEC EDGAR | NVCR 8-K: 2.02 and (SEC Filing) |
| 2026-04-22 | +2.3% | news | GuruFocus | NovoCure Ltd (NVCR) Stock Up 6.5% and Still Undervalued -- GF Sc - GuruFocus |
| 2025-07-30 | +2.2% | news | Seeking Alpha | NovoCure's Wearable Oncology Edge And Compelling Valuation |
| 2026-01-13 | -2.2% | news | Seeking Alpha | Why NovoCure Is Failing To Disrupt NSCLC |
| 2026-01-13 | -2.2% | analyst | Investing.com | NovoCure stock holds steady as H.C. Wainwright reiterates Buy rating - Investing.com |
| 2022-04-13 | +2.1% | legal | SEC EDGAR | NVCR 8-K: 5.02 (SEC Filing) |
| 2026-03-26 | -2.1% | news | MT Newswires | Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Ongoing Middle East Tensions |
| 2026-03-26 | -2.1% | news | MT Newswires | NovoCure Says Phase 2 Trial of TTFields With Atezolizumab Meets Primary Endpoint in Pancreatic Cancer |
| 2026-03-26 | -2.1% | news | Business Wire | Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer |
| 2026-03-26 | -2.1% | news | Simply Wall St. | Is NovoCure (NVCR) Now Pricing In Too Much Pessimism After Prolonged Share Price Slump |
| 2026-03-26 | -2.1% | news | Seeking Alpha | Novocure mid-stage trial for electric fields device succeeds in pancreatic cancer |
| 2026-03-26 | -2.1% | news | Stock Titan | Vanguard disaggregates ownership reporting for Novocure (NVCR) after realignment - Stock Titan |
| 2026-03-26 | -2.1% | news | Stock Titan | Pancreatic cancer trial posts 74.4% disease control with Novocure - Stock Titan |
| 2026-03-26 | -2.1% | news | Stock Titan | Novocure (NASDAQ: NVCR) reports positive PANOVA-4 pancreatic cancer data - Stock Titan |
| 2026-03-26 | -2.1% | news | Benzinga | NovoCure Tumor Treating Fields Shows Improved Outcomes In Tough Pancreatic Cancer - Benzinga |
| 2026-03-24 | -2.0% | earnings | Zacks | LENZ Therapeutics, Inc. (LENZ) Reports Q4 Loss, Misses Revenue Estimates |
| 2026-03-02 | -1.9% | news | Zacks | NovoCure (NVCR) Reliance on International Sales: What Investors Need to Know |
| 2026-03-02 | -1.9% | earnings | Seeking Alpha | NovoCure Limited 2025 Q4 - Results - Earnings Call Presentation |
| 2026-03-02 | -1.9% | news | Stock Titan | Japan’s health system to cover wearable lung cancer device Optune Lua - Stock Titan |
| 2022-10-27 | +1.6% | legal | SEC EDGAR | NVCR 8-K: 2.02 and (SEC Filing) |
| 2025-06-06 | +1.6% | legal | SEC EDGAR | NVCR 8-K: 5.02, 5.07 (SEC Filing) |
| 2025-10-17 | +1.6% | analyst | Seeking Alpha | NovoCure: Buy Rating As Pipeline Gains Drive Renewed Momentum |
| 2025-05-24 | +1.4% | news | Seeking Alpha | NovoCure: Loading Up On Growth Catalysts |
| 2026-01-14 | +1.3% | news | Seeking Alpha | NovoCure Limited (NVCR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript |
| 2025-04-24 | +1.3% | legal | SEC EDGAR | NVCR 8-K: 2.02 and (SEC Filing) |
| 2026-02-27 | -1.2% | executive | Stock Titan | Novocure CEO and CFO to field investor questions at Leerink event - Stock Titan |
| 2023-03-29 | -1.2% | legal | SEC EDGAR | NVCR 8-K: 5.02 and (SEC Filing) |
| 2025-08-26 | +1.1% | news | Seeking Alpha | ImmunityBio rises on data for NK cell therapy, device combo for glioblastoma |
| 2024-06-10 | -1.0% | legal | SEC EDGAR | NVCR 8-K: 5.02, 5.07 (SEC Filing) |
| 2022-04-28 | +0.8% | legal | SEC EDGAR | NVCR 8-K: 2.02 and (SEC Filing) |
| 2022-11-04 | -0.8% | legal | SEC EDGAR | NVCR 8-K: 8.01 (SEC Filing) |
| 2021-06-11 | +0.7% | legal | SEC EDGAR | NVCR 8-K: 5.02 and 5.07 (SEC Filing) |
| 2021-04-29 | -0.7% | legal | SEC EDGAR | NVCR 8-K: 2.02 and (SEC Filing) |
| 2022-04-07 | +0.6% | legal | SEC EDGAR | NVCR 8-K: 8.01 and (SEC Filing) |
| 2024-07-25 | +0.6% | legal | SEC EDGAR | NVCR 8-K: 2.02 and (SEC Filing) |
| 2025-09-10 | -0.6% | news | Seeking Alpha | NovoCure Limited (NVCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) |
| 2026-03-03 | -0.6% | executive | Stock Titan | NovoCure (NVCR) COO offloads 1,963 shares in tax sell-to-cover - Stock Titan |
| 2026-03-03 | -0.6% | news | Stock Titan | NovoCure (NASDAQ: NVCR) General Counsel receives 17,755-share performance award - Stock Titan |
| 2026-03-03 | -0.6% | news | Stock Titan | Tax-withholding sale of 1,029 NovoCure (NASDAQ: NVCR) shares by ex-CMO - Stock Titan |
| 2026-03-03 | -0.6% | executive | Stock Titan | Equity awards and tax share withholding for NovoCure (NVCR) ex-CEO Cordova - Stock Titan |
| 2026-03-03 | -0.6% | executive | Stock Titan | NovoCure (NVCR) CEO reports RSU vesting and tax-cover share sales - Stock Titan |
| 2026-04-12 | +0.3% | legal | Stock Titan | NVCR SEC Filings - Novocure 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2024-01-04 | -0.3% | legal | SEC EDGAR | NVCR 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-04-24 | — | legal | SEC EDGAR | NVCR 8-K: 5.02 and (SEC Filing) |
| 2026-04-24 | — | expansion | Stock Titan | CEO Frank Leonard's new NovoCure (NASDAQ: NVCR) contract outlines pay - Stock Titan |